Summary
This review, published in Frontiers in Pharmacology (2025), synthesises preclinical and clinical evidence on the therapeutic potential of natural products — likely including polyphenols, alkaloids, terpenoids, and flavonoids — in the context of Alzheimer's disease. Drawing on in vitro, in vivo, and clinical study designs, it evaluates mechanistic pathways relevant to neurodegeneration, including amyloid and tau pathology, neuroinflammation, and oxidative stress. The paper provides a consolidated assessment of where natural compound research stands relative to clinical translation, and likely highlights gaps between preclinical promise and clinical evidence.
UK applicability
Whilst not UK-specific, the findings are broadly relevant to UK dementia research priorities and public health policy, given that Alzheimer's disease represents a significant and growing burden on the NHS. Interest in dietary and plant-derived interventions as adjunct or preventive strategies is reflected in UK nutritional and neuroscience research agendas.
Key measures
Amyloid-beta aggregation inhibition; tau phosphorylation; neuroinflammatory markers; oxidative stress indices; cognitive function scores (e.g. MMSE, ADAS-Cog); cell viability assays; animal behavioural outcomes
Outcomes reported
The review examines the efficacy of natural product-derived compounds in ameliorating Alzheimer's disease pathology, summarising findings from in vitro mechanistic studies, in vivo animal models, and available clinical trials. It likely reports on outcomes including amyloid-beta reduction, tau phosphorylation, neuroinflammation, oxidative stress markers, and cognitive performance.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.